GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease
WithdrawnPhase 2NCT02377336
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will evaluate the effect of GS-6615 in adults with chronic stable angina and coronary artery disease (CAD) receiving a stable daily dose of up to 2 antianginal medications. The study will consist of two periods: a 1 to 3 week Qualifying Period and a Treatment Period lasting 13 days (± 3 days). During the Qualifying Period and at the end of the Treatment Period, participants will undergo exercise tolerance testing.
Study details
- Official title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of GS-6615 in Subjects With Chronic Stable Angina and Coronary Artery Disease
- Conditions
- Interventions
- Drug: GS-6615
- Drug: Placebo
- Sponsor
- Gilead Sciences
- Start date
- 2015-05
- Primary completion
- 2016-08
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Able to perform a standardized treadmill exercise protocol * At least a 3 month history of chronic stable angina triggered by physical effort and relieved by rest and/or short-acting nitroglycerin * Coronary artery disease (CAD) documented by one or more of the following: * Angiographic evidence (either invasive or noninvasive) of ≥ 50% stenosis of one or more major coronary arteries * History of myocardial infarction (MI) documented by positive creatine kinase-myocardial band (CK-MB) enzymes, troponins, or electrocardiogram (ECG) changes * Noninvasive imaging stress test diagnostic of CAD (eg, nuclear perfusion scan, stress echocardiogram, stress cardiac magnetic resonance scan) * Stable antianginal treatment with up to 2 antianginal agents Exclusion Criteria: * Inability to exercise or having exercise limitation due to other co-morbidities that may interfere with ability to perform required exercise tolerance testing (ETT) * Presence of electrocardiographic or other abnormalities that interfere with ECG interpretation or may cause a false positive stress test * History of heart failure as defined by New York Heart Association Class III-IV and/or known left ventricular ejection fraction ≤ 45% * History of severe disabling angina as defined by Canadian Cardiovascular Society Class IV * Myocardial infarction, acute coronary syndrome or coronary revascularization within 3 months prior to screening, or planned coronary revascularization during the study period * Stroke or transient ischemic attack within 6 months prior to screening * Chronic persistent atrial fibrillation * Uncontrolled hypertension (seated systolic blood pressure (SBP) \> 160 mm Hg or diastolic blood pressure (DBP) \> 110 mm Hg) * Body mass index (BMI) ≥ 36 kg/m\^2
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02377336